Research Collaboration and Exclusive License Agreement - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) Target	Dec. 31, 2021 USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]
Deferred revenue current	$ 5,406	$ 5,163
Accounts receivable outstanding	0	0
Merck Agreement First Collaboration Target
Research And Development Arrangement Contract To Perform For Others [Line Items]
Aggregate transaction price allocated to unsatisfied performance obligation	500
Merck Agreement Second Collaboration Target
Research And Development Arrangement Contract To Perform For Others [Line Items]
Aggregate transaction price allocated to unsatisfied performance obligation	$ 10,000
Merck Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Number of collaboration targets | Target	2
Non-refundable and non-creditable upfront fee	$ 8,000
Payable upon selection of second collaboration target	8,000
Milestone payments	285,000
Transaction price	11,400
Reimbursable research program funding for collaboration target	3,400
Revenue recognized	8,600	$ 3,600
Deferred revenue	7,600
Deferred revenue current	5,400
Merck Agreement | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments per collaboration target	142,500
Milestone payments upon successful completion of certain commercial milestones	$ 350,000